Infectious Disease

Ivermectin efficient for COVID-19 prophylaxis, remedy

December 08, 2020

3 min read

ADD SUBJECT TO EMAIL ALARMS

Receive an email when new articles are published

Please enter your email address to receive an email when new articles are published . “data-action =” subscribe “> subscribe

We could not process your request. Please try again later. If you continue to have this problem, please contact customerservice@slackinc.com.

Back to Healio

According to the Frontline COVID-19 Critical Care Alliance, numerous studies have provided evidence of the use of ivermectin to prevent and treat COVID-19.

Paul Marik, MD, FCCM, FCCP, The Alliance’s founder and professor and director of the pulmonary and critical care unit at Eastern Virginia Medical School said ivermectin was “a safe drug that is extremely cheap.”

According to the Frontline COVID-19 Critical Care Alliance, numerous studies have provided evidence of the use of ivermectin to prevent and treat COVID-19. Source: Adobe Stock.

He added that “what is really remarkable – this was a gift to us – ivermectin has high activity against COVID-19.”

In a news conference, researchers said ivermectin is an FDA-approved anti-parasitic drug that has been around for about 40 years and previously earned researchers a Nobel Prize.

Ivermectin is a key factor in the Alliance’s I-MASK + protocol for the prophylaxis and early treatment of outpatients with COVID-19. In the protocol, those at high risk for COVID-19 infection are given ivermectin at 0.2 mg / kg on day 1 and day 3 and weekly for 4 weeks; those exposed to COVID-19 are given the same dose on days 1 and 3; and both groups received daily doses of vitamin D3, vitamin C, quercetin, zinc, and melatonin. For early outpatients with COVID-19, the protocol calls for a dose of ivermectin of 0.2 mg / kg on day 1 and day 3 along with the same daily vitamins and 325 mg of aspirin per day.

During the press conference, Marik said that much of the data available on ivermectin in the treatment and prevention of COVID-19 has been released since August. This was the last time the NIH updated its recommendations for the novel coronavirus.

So far, Marik said, studies have shown ivermectin to be effective in preventing COVID-19 infection before and after exposure to COVID-19. He also said it has been shown to be effective in treating the virus in the early symptomatic stages and in patients hospitalized with COVID-19.

In a literature review, Marik and colleagues explained all available clinical trial results on ivermectin in COVID-19 and concluded that the drug has benefits in the prevention and treatment of COVID-19 infections.

For example, Marik and colleagues found that a randomized controlled trial in Egypt found that among healthcare and household contacts with COVID-19 patients, only 2% of those who received ivermectin and wore PPE tested positive for the novel coronavirus compared to 10% of contacts given only PSA.

Marik and colleagues also described a randomized controlled trial with hospital patients that was carried out at the same time as the prophylaxis study. The study included 400 patients divided into four groups – two consisting of patients with mild to moderate disease and two consisting of seriously ill patients. Patients with mild to moderate illness received one dose of ivermectin twice daily in addition to standard care or one dose of hydroxychloroquine in addition to standard care. The researchers found that the rate of disease progression was significantly lower in those who received ivermectin (1% versus 22%). Seriously ill patients received standard care plus ivermectin or hydroxychloroquine. The researchers found that in addition to lower rates of COVID-19 disease progression, the ivermectin group had a lower death rate (2% vs 20%) in the ivermectin group (4% vs 30%).

Pierre Kory, MD, MPA, An associate professor of medicine and an intensive care physician at St. Luke’s Medical Center in Milwaukee, Wisconsin, said that in the days since their review was written, more studies have been published supporting the use of ivermectin in patients with COVID-19.

“All studies showed positive benefits – the majority showed a decrease in mortality, a decrease in hospital admissions,” said Kory.

Given the positive data for ivermectin in COVID-19, the researchers urged national and global health authorities – including the NIH, WHO, and CDC – to investigate the data.

“We appeal to these national and global health authorities,” said Marik. “Please review the data and provide guidance to health care workers around the world so they can prescribe this drug.”

References

ADD SUBJECT TO EMAIL ALARMS

Receive an email when new articles are published

Please enter your email address to receive an email when new articles are published . “data-action =” subscribe “> subscribe

We could not process your request. Please try again later. If you continue to have this problem, please contact customerservice@slackinc.com.

Back to Healio

COVID-19 Resource Center

COVID-19 Resource Center

Related Articles